Literature DB >> 15222661

Comparison of cytochrome P450 2C9 genotyping methods and implications for the clinical laboratory.

Christina L Aquilante1, Maximilian T Lobmeyer, Taimour Y Langaee, Julie A Johnson.   

Abstract

STUDY
OBJECTIVE: To compare the accuracy, speed, and cost of two methodologies used for genotyping known variants in the cytochrome P450 (CYP) 2C9 metabolizing enzyme gene.
DESIGN: Comparative study.
SETTING: University research center. SAMPLES: Fifteen-milliliter mouthwash samples collected from 253 subjects participating in a warfarin pharmacogenomic study. INTERVENTION: Genotyping for the isoleucine-to-leucine change at codon 359 (Ile359Leu [*3] polymorphism) was performed by using the Pyrosequencing and polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP) methods in all 253 samples. Genotyping for the arginine-to-cysteine change at codon 144 (Arg144Cys [*2] polymorphism) was performed by using Pyrosequencing in all samples and by PCR-RFLP in a random subset of 136 samples.
MEASUREMENTS AND MAIN RESULTS: Comparisons of genotyping success rates, time efficiency, and cost analyses were conducted for Pyrosequencing and PCR-RFLP at each variant site. Pyrosequencing and PCR-RFLP produced similar success rates on the first genotyping attempt for the Arg144Cys variant (93.3% vs 90.4%, respectively) and the Ile359Leu variant (83.8% vs 79.1%, respectively). With Pyrosequencing, genotyping 96 samples for either polymorphism could be performed in 1 hour. In contrast, genotyping 96 samples by RFLP took 10 hours for the Arg144Cys variant and 20 hours for the Ile359Leu variant. Total cost/sample for Arg144Cys genotyping was dollars 1.90 with PCR-Pyrosequencing and dollars 3.14 with PCR-RFLP. Total cost/sample for Ile359Leu genotyping was dollars 1.88 with PCR-Pyrosequencing and dollars 10.18 with PCR-RFLP
CONCLUSION: Compared with RFLP, genotype determination by Pyrosequencing is a more time-efficient, cost-effective, and robust method for CYP2C9 genotyping. Because of its wide applicability and ease of use, Pyrosequencing is a promising technology for future pharmacogenomic investigations.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15222661     DOI: 10.1592/phco.24.8.720.36074

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  10 in total

Review 1.  Pharmacogenetics in psychiatry: are we ready for widespread clinical use?

Authors:  Maria J Arranz; Shitij Kapur
Journal:  Schizophr Bull       Date:  2008-08-27       Impact factor: 9.306

2.  Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients.

Authors:  Mohamed Hossam A Shahin; Sherief I Khalifa; Yan Gong; Lamiaa N Hammad; Mohamed T H Sallam; Mostafa El Shafey; Shawky S Ali; Mohamed-Eslam F Mohamed; Taimour Langaee; Julie A Johnson
Journal:  Pharmacogenet Genomics       Date:  2011-03       Impact factor: 2.089

3.  Genetic-based dosing in orthopedic patients beginning warfarin therapy.

Authors:  Eric A Millican; Petra A Lenzini; Paul E Milligan; Leonard Grosso; Charles Eby; Elena Deych; Gloria Grice; John C Clohisy; Robert L Barrack; R Stephen J Burnett; Deepak Voora; Susan Gatchel; Amy Tiemeier; Brian F Gage
Journal:  Blood       Date:  2007-03-26       Impact factor: 22.113

4.  Novel single nucleotide polymorphism in CYP2C9 is associated with changes in warfarin clearance and CYP2C9 expression levels in African Americans.

Authors:  Wenndy Hernandez; Keston Aquino-Michaels; Katarzyna Drozda; Shitalban Patel; Young Jeong; Harumi Takahashi; Larisa H Cavallari; Minoli A Perera
Journal:  Transl Res       Date:  2014-11-22       Impact factor: 7.012

5.  Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy.

Authors:  N S Ferder; C S Eby; E Deych; J K Harris; P M Ridker; P E Milligan; S Z Goldhaber; C R King; T Giri; H L McLeod; R J Glynn; B F Gage
Journal:  J Thromb Haemost       Date:  2009-10-30       Impact factor: 5.824

6.  VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients.

Authors:  G Oner Ozgon; T Y Langaee; H Feng; N Buyru; T Ulutin; A C Hatemi; A Siva; S Saip; J A Johnson
Journal:  Eur J Clin Pharmacol       Date:  2008-06-10       Impact factor: 2.953

7.  Genotyping the GGGCGG tandem repeat promoter polymorphism in the 5-lipoxygenase enzyme gene (ALOX5) by pyrosequencing assay.

Authors:  Anzeela M Schentrup; Hooman Allayee; John J Lima; Julie A Johnson; Taimour Y Langaee
Journal:  Genet Test Mol Biomarkers       Date:  2009-06

8.  Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin.

Authors:  B F Gage; C Eby; J A Johnson; E Deych; M J Rieder; P M Ridker; P E Milligan; G Grice; P Lenzini; A E Rettie; C L Aquilante; L Grosso; S Marsh; T Langaee; L E Farnett; D Voora; D L Veenstra; R J Glynn; A Barrett; H L McLeod
Journal:  Clin Pharmacol Ther       Date:  2008-02-27       Impact factor: 6.875

Review 9.  Treatment of the first episode of schizophrenia: an update on pharmacologic and psychological interventions.

Authors:  Benedicto Crespo-Facorro; Rocío Pérez-Iglesias; Cesar González-Blanch; Ignacio Mata
Journal:  Curr Psychiatry Rep       Date:  2008-06       Impact factor: 5.285

10.  Sequence analysis of the N-acetyltransferase 2 gene (NAT2) among Jordanian volunteers.

Authors:  Yazun Bashir Jarrar; Ayat Ahmed Balasmeh; Wassan Jarrar
Journal:  Libyan J Med       Date:  2018-12       Impact factor: 1.657

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.